Ovarian Tunuor

UK-based PsiOxus Therapeutics (PsiOxus) has started its Octave trial of paclitaxel combined with the oncolytic virotherapy enadenotucirev to treat patients with ovarian cancer.

The trial is designed to evaluate the safety, tolerability and efficacy of intraperitoneal enadenotucirev when combined with intravenous paclitaxel.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company noted that in earlier Phase I trials enadenotucirev has been shown to selectively infect cancer cells when administered by intravenous infusion.

Platinum-resistant ovarian cancer patients are being enrolled in the Octave trial at clinical centres in the UK and Spain.

Patients in Phase Ia received intra-peritoneal enadenotcuriev on its own. The trial’s Phase Ib component will now examine the combination with intravenous paclitaxel.

Last year, the European Medicines Agency (EMA) awarded enadenotucirev orphan drug status when combined with paclitaxel to treat epithelial ovarian cancer in Europe.

Pre-clinical trials have shown the combination to be successful in models of platinum-resistant ovarian cancer, and to have potentially improved efficacy over monotherapy alone.

"This combination has the potential to offer patients an improved therapeutic benefit in a disease population where there is a high unmet need."

PsiOxus CEO Dr John Beadle said: "This marks an important milestone in the development of enadenotucirev for ovarian cancer. The combination with paclitaxel will bring together two agents with very different, but complementary, mechanisms of action.

"This combination has the potential to offer patients an improved therapeutic benefit in a disease population where there is a high unmet need."

The company has also started its Spice trial to evaluate a therapy combining Merck’s Keytruda (pembrolizumab) and EnAd.

Currently being conducted in the US, the trial is to evaluate enadenotucirev’s ability to reverse resistance to checkpoint inhibitors for certain tumour types, including metastatic colorectal cancer.


Image: Micrograph of a mucinous ovarian carcinoma. Photo: courtesy of Nephron.